{
    "clinical_study": {
        "@rank": "70641", 
        "arm_group": {
            "arm_group_label": "ADVATE - 2mL"
        }, 
        "brief_summary": {
            "textblock": "This is a Post-Authorization Safety Surveillance (PASS) study designed to collect data on\n      the safety and effectiveness of ADVATE reconstituted in 2 mL Sterile water for injection\n      (SWFI) during routine clinical practice in children until 12 years of age. This surveillance\n      study is a post-licensure commitment for ADVATE reconstituted in 2 mL SWFI."
        }, 
        "brief_title": "ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hemophilia A", 
            "Congenital Factor VIII (FVIII) Deficiency"
        ], 
        "condition_browse": {
            "mesh_term": "Hemophilia A"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Severe or moderately severe hemophilia A (baseline Factor VIII (FVIII) \u2264 2%)\n\n          -  \u226412 years of age\n\n          -  Participant's legally authorized representative(s) has provided written informed\n             consent\n\n          -  Participant is prescribed ADVATE and will only receive ADVATE reconstituted in 2 mL\n             sterile water for injection (SWFI)\n\n          -  Documented history of prior exposure to ADVATE\n\n          -  Documented evidence of negative inhibitor test result during \u226410 EDs prior to study\n             entry\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity to the active substance or to any of the excipients\n\n          -  Known allergic reaction to mouse or hamster proteins\n\n          -  Participant has a requirement for a major surgical procedure at the time of\n             enrollment\n\n          -  Participant has no prior exposure to a FVIII concentrate\n\n          -  Participant currently being treated with an immune tolerance induction (ITI) regimen\n\n          -  Participant has been diagnosed with an inherited or acquired hemostatic defect other\n             than hemophilia A (eg, qualitative platelet defect or von Willebrand disease)\n\n          -  Participant has participated in another clinical study involving an investigational\n             product (IP) or investigational device within 30 days prior to enrollment or is\n             scheduled to participate in another clinical study involving an IP or investigational\n             device or PASS registry during the course of this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "12 Years", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The study population will include 60 evaluable participants aged \u2264 12 years with severe or\n        moderately severe hemophilia A (Factor VIII (FVIII) \u2264 2%) with documented prior exposure\n        to FVIII concentrates."
            }
        }, 
        "enrollment": {
            "#text": "73", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02093741", 
            "org_study_id": "061101"
        }, 
        "intervention": {
            "arm_group_label": "ADVATE - 2mL", 
            "description": "The investigators shall determine all treatment regimens according to product labeling information and standard practice.", 
            "intervention_name": "Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]", 
            "intervention_type": "Biological", 
            "other_name": [
                "ADVATE", 
                "Antihemophilic Factor (Recombinant)- Plasma/albumin free method (rAHF-PFM)"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Factor VIII"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Leeds", 
                        "country": "United Kingdom", 
                        "state": "West Yorkshire", 
                        "zip": "LS1 3EX"
                    }, 
                    "name": "Leeds General Infirmary"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United Kingdom", 
                        "zip": "B4 6NH"
                    }, 
                    "name": "Birmingham Children's Hospital NHS Trust"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "WC1N 3JH"
                    }, 
                    "name": "Great Ormond Street Hospital for Children NHS Trust"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_groups": "1", 
        "official_title": "ADVATE 2 mL (Reconstituted in 2 mL SWFI) POST-AUTHORIZATION SAFETY SURVEILLANCE STUDY", 
        "overall_contact": {
            "email": "andras_nagy@baxter.com", 
            "last_name": "Andras Nagy"
        }, 
        "overall_official": {
            "affiliation": "Baxter Healthcare Corporation", 
            "last_name": "Vadim Romanov, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "European Union: European Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of all local and general, hypersensitivity and infusion-related reactions, irrespective of product-related causality for the adverse events (AEs).", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02093741"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Causally related = possibly or probably related", 
                "measure": "Number and type of adverse events (or adverse experiences) (AEs) considered by the investigator to be causally related to ADVATE reconstituted in 2 mL sterile water for injection (SWFI)", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Number of Factor VIII (FVIII) inhibitors in all participants", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Number of Factor VIII (FVIII) inhibitors in Previously Treated Patients (PTPs) (> 50 Exposure Days (EDs)) with baseline Factor VIII (FVIII) < 1% and no history of FVIII inhibitors prior to study entry", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Number of Factor VIII (FVIII) inhibitors in Previously Treated Patients (PTPs) (> 50 Exposure Days (EDs)) with baseline Factor VIII (FVIII) \u2264 2% and no history of FVIII inhibitors prior to study entry", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Subjective hemostatic effectiveness rating of excellent, good, fair, or none for each bleeding episode treated", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Number of bleeding episodes treated with 1, 2, 3, \u2265 4 infusions of ADVATE reconstituted in 2 mL sterile water for injection (SWFI)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Total units of ADVATE reconstituted in 2 mL sterile water for injection (SWFI) administered to treat each bleeding episode", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Overall effectiveness of prophylaxis in participants who are on a prophylactic regimen", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Global assessment rating = excellent, good, fair, or none", 
                "measure": "Global assessment rating of hemostatic effectiveness of ADVATE reconstituted in 2 mL sterile water for injection (SWFI) in surgical or dental procedures", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Change in Factor VIII (FVIII) treatment satisfaction and preference ratings from caregiver between ADVATE reconstituted in 5 mL and 2 mL sterile water for injection (SWFI)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Change in Factor VIII (FVIII) infusion volume and time to mix and infuse FVIII treatment between ADVATE reconstituted in 5 mL and 2 mL sterile water for injection (SWFI)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Baxter Healthcare Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Baxter Healthcare Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}